KalVista Pharmaceuticals, Inc. (KALV)
| Market Cap | 312.37M |
| Revenue (ttm) | 5.40M |
| Net Income (ttm) | -37.12M |
| Shares Out | 17.91M |
| EPS (ttm) | -2.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $16.24 |
| Previous Close | $16.98 |
| Change ($) | -0.74 |
| Change (%) | -4.36% |
| Day's Open | 17.20 |
| Day's Range | 16.07 - 18.18 |
| Day's Volume | 143,957 |
| 52-Week Range | 5.80 - 19.47 |
Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.
KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, a...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...
Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.
Prospects Appear Bright for Small Drug Industry in 2020
Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are seen moving to the downside Monday.
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).
KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.
KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
KALV is an early stage company without much efficacy data, but early data for its drug candidates are promising.
Clinical-stage biopharma KalVista Pharmaceuticals has lost approximately 40% of its value since early April as it entered a news vacuum.
KalVista's valuation continues to drift but it has two things going for it: cash runway & catalysts.
KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Shares of KalVista have fallen nearly 30% this month due to sector weakness and insider sales (presumably).
KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.
About KALV
KalVista Pharmaceuticals, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treati... [Read more...]
| Industry Biotechnology | |
| CEO Thomas Crockett | Employees 56 |
| Stock Exchange NASDAQ | Ticker Symbol KALV |
Financial Performance
In 2020, KALV's revenue was $12.69 million, a decrease of -21.31% compared to the previous year's $16.13 million. Losses were -$29.12 million, 39.9% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is 29.86, which is an increase of 83.87% from the latest price.